Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice
Agnese Losurdo(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Rita De Sanctis(Humanitas University), Massimo Roncalli(Fondazione Humanitas per la Ricerca), Wolfgang Gatzemeier(IRCCS Humanitas Research Hospital), Bethania Fernandes(Humanitas University), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Alberto Testori(IRCCS Humanitas Research Hospital), Corrado Tinterri(Humanitas University), Valentina Errico(IRCCS Humanitas Research Hospital), Elisa Agostinetto(Université Libre de Bruxelles), Giovanna Masci(Humanitas University)
Cited by 15
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670